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Abstract ADP-ribosyl cyclases (ADPRCs) catalyse the
conversion of nicotinamide adenine dinucleotide to cyclic
adenosine diphosphoribose (cADPR) which is a second mes-
sengerinvolvedinCa
2+mobilisation fromintracellular stores.
Viaits interaction withthe ryanodine receptorCa
2+channel in
the heart, cADPR may exert arrhythmogenic activity. To test
this hypothesis, we have studied the effect of novel cardiac
ADPRCinhibitorsinvitro and in vivoinmodelsofventricular
arrhythmias. Using a high-throughput screening approach on
cardiac sarcoplasmic reticulum membranes isolated from pig
and rat and nicotinamide hypoxanthine dinuleotide as a sur-
rogatesubstrate,we haveidentified potentandselectiveinhib-
itors of an intracellular, membrane-bound cardiac ADPRC
that are different from the two known mammalian ADPRCs,
CD38andCD157/Bst1.Weshowthattwostructurallydistinct
cardiac ADPRC inhibitors, SAN2589 and SAN4825, prevent
the formation of spontaneous action potentials in guinea pig
papillary muscle in vitro and that compound SAN4825 is
active in vivo in delaying ventricular fibrillation and cardiac
arrestinaguineapigmodelofCa
2+overload-inducedarrhyth-
mia. Inhibition of cardiac ADPRC prevents Ca
2+ overload-
induced spontaneous depolarizations and ventricular fibrilla-
tionand may thusprovide a novel therapeutic principle for the
treatment of cardiac arrhythmias.
Keywords CyclicADP-ribose .ADP-ribosylcyclase .Anti-
arrhythmicagents .Ventriculararrhythmias .Cachannel
Introduction
Cyclic adenosine diphosphoribose (cADPR) was first identi-
fiedasaCa
2+-mobilisingsecondmessengerinseaurchineggs
derived from nicotinamide adenine dinucleotide (NAD, Clap-
per et al. 1987; Lee et al. 1989). cADPR-regulated Ca
2+
release from intracellular Ca
2+stores plays a role in a variety
of physiological processes such as insulin secretion(Takasawa
et al. 1993), Tcell activation (Howard et al. 1993), regulation
of vascular tone (Geiger et al. 2000) or cardiac excitation–
contraction coupling (Rakovic et al. 1996). The mechanism
by which cADPR influences intracellular Ca
2+ mobilisation
remains controversial (Venturi et al. 2010).
The enzyme catalyzing cADPR formation, ADP-ribosyl
cyclase (ADPRC), was first purified from Aplysia californica
(sea slug) ovotestis (Lee and Aarhus 1991; Hellmich and
Strumwasser 1991).Based on sequence comparison,two mam-
malian homologs have been identified: the CD38 surface anti-
gen, a marker of lymphocyte activation and differentiation, and
CD157/BST-1 (bone marrow stromal antigen 1, States et al.
1992; Itoh et al. 1994;L e e2000) that arose from a gene
duplication event (Malavasi et al. 2006). The three enzymes
have only about 30 % sequence identity but contain a set of ten
cysteine residues that are strongly conserved across species.
Recently, ADPR cyclase activites with properties distinct
from CD38 and CD157 have been identified in a variety of
mammalian tissues, for example, in brain (Ceni et al. 2003),
retinal rod outer segments (Fabiano et al. 2011), heart (Xie et
al. 2005), vascular smooth muscle (de Toledo et al. 2000),
skeletal muscle (Bacher et al. 2004) and kidney (Nam et al.
2006). They are located intracellularly and are, for example,
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2+ ions. Both
cADPR and NAD concentrations were not significantly dif-
ferentinheartandkidneyand only mildlyreduced inlungand
brain of CD38−/− mice compared to wild-type controls
(Young et al. 2006). So far, the molecular correlates of these
ADPRC activities have not been determined.
The role of cADPR for Ca
2+ release via the cardiac ryano-
dine receptor (RyR2) has been extensively investigated. First
evidence for an activation of RyR2 by cADPR in cardiac
microsomes was provided by Meszaros et al. (1993). In intact
cardiomyocytes from rats and guinea pigs, cADPR injection
or photorelease led to an increase in the magnitude of Ca
2+
transients, an augmentation of contraction and an increase in
the frequency of occurrence of spontaneous Ca
2+ sparks. All
of these phenomena were prevented in the presence of com-
petitive antagonists of cADPR-induced Ca
2+ mobilisation, 8-
amino-cADPR or 8-bromo-cADPR (Rakovic et al. 1996;I i n o
et al. 1997; Cui et al. 1999).
Additionally, it was shown thatcADPR isa mediatorofthe
sustained phase of the angiotensin II-induced rise in intracel-
lular Ca
2+ and angiotensin II-stimulated hypertrophy of rat
cardiomyocytes (Gul et al. 2008) and that 4,4′-dihydroxyazo-
benzene, an inhibitor of cellular cADPR formation, can block
angiotensin II-induced cardiac hypertrophy in vivo in a two-
kidney one-clip rat model (Gul et al. 2009).
In intact guinea pig cardiomyocytes, under Ca
2+ overload
through high concentrations of the beta-adrenoreceptor agonist
isoproterenol or the Na
+/K
+-ATPase inhibitor ouabain, sponta-
neous generation of action potentials and Ca
2+ waves was
suppressed in the presence of 8-amino-cADPR. Moreover,
cADPR infusion was associated with spontaneous electrical
and contractile activity, pointing towards the possibility that
cADPR may exert arrhythmogenic activity in the heart
(Rakovic et al. 1999).
Here, we show that a potent and specific inhibitor of
cardiac ADPR cyclase, a protein that is distinct from CD38
or the archetypical ADPR cyclase from A. californica,c a n
suppress Ca
2+ overload-induced arrhythmic events both in
vitro and in vivo. Thus, cardiac ADPR cyclase inhibitors
may have a therapeutic potential as anti-arrhythmic agents
in, e.g., catecholaminergic polymorphic ventricular tachycar-
dia (CPVT) or congestive heart failure.
Methods
Purification of recombinant human CD38 and A. californica
ADPR cyclase
The full-length cDNA of human CD38 and ADPR cyclase
from A. californicawere usedto clone expression constructs.
In ORF coding for the extracellular domain of human CD38
Arg45-Ile300 (P28907), A. californica ADPRC Ile25-
Ala282 (P29241) was cloned in frame with an insect prepro-
melitin signal sequenceanda 6xHistag at theC-terminal end
of the coding proteins and ligated into the multiple cloning
site of the baculovirus transfer vector (Kitts and Possee
1993) pVL1393 vector (AB Vector). After cotransfection
of plasmids with baculovirus DNA (flashBAC gold, Oxford
Expression Technologies), virus was amplificated in two
steps in Spodoptera frugiperda cell line SF9 (Vaughn et al.
1977) in SF900II medium (Invitrogen) supplemented with
5 % fetal calf serum (FCS). The recombinant virus was
harvested 5 days post-transfection. The virus titres were
determined by plaque assay method (Brown and Faulkner
1977) and reached about 1×10
8 pfu/ml.
A. californica ADPRC was expressed for 72 h post
infection at a multiplicity of infection (MOI) of 3 in 1.4×
10
6 cells/ml in High Five cells growing in ExCell405 me-
dium at a 1-l scale using vented 3,000-ml flasks (Corning) at
100 rpm. Human CD38 extracellular domain was expressed
for 72 h post infection at 1 MOI in 1.6×10
6 cells/ml in SF9
cells cultivated in SF900II medium without FCS in 1-l scale
in vented 3,000-ml flasks (Corning) at 100 rpm at 27°C.
All following purification steps were carried out at 4°C
using an ÄKTA explorer system (GE) for chromatography
steps: His-tagged proteins from the clarified insect cell super-
natant were bound directly to a metal-chelating ligand
(Hochuli et al. 1988) using a 1-ml HiTrap columns HP (GE)
with a flow rate of 1 ml/min. After washing with 20 CV of
buffer consisting 300 mM NaCl and 50 mM Tris/HCl pH 7.5,
bound protein was eluted within a linear gradient from 0–
100 % buffer which is composed of 300 mM NaCl, 50 mM
Tris/HCl pH 7.5 and 500 mM imidazole. Fractions were
collected, analysed on SDS-PAGE, pooled and dialyzed over-
night against 50 mM Tris/HCl pH 7.5. The sample was
filtrated (0.22 μm, Sartorius) to separate the precipitated pro-
tein from contamination, and protein was applied on a cation
exchanger, a HiTrap S HP (GE) 1-ml column. Bound protein
waselutedwithinalineargradientfrom0mMNaClupto1M
NaCl in 50 mM Tris/HCl pH 7.5. After analysis of eluted
fractions, the protein solution had a purity of about 80 % and
was further enriched by size exclusion chromatography on
Superdex 16/60 200 HR (GE) using a buffer composed of
300 mM NaCl and 50 mM Tris/HCl pH 7.5.
Animal investigations
All investigations with animals conform to the Guide for the
Care and Use of Laboratory Animal published by the US
National Institute of Health (NIH publication no. 85–23,
revised 1996) and were performed by technicians specifi-
cally trained and experienced in animal care following ap-
proval by the Ethical Review Board of the State of Hessen
and in accordance with the German animal protection law
(application reference HMR-4A/Anzeige47).
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Sarcoplasmic reticulum membranes from pig and rat heart
were prepared according to the following protocol (Kranias
et al. 1982): Pigs were anaesthetized with a single bolus of
16 mg/kg pentobarbital and then euthanised by a single bolus
injection of 10 ml saturated KCl. Immediately thereafter, the
thorax was opened, and the heart was removed and put into
ice-coldmediumI(30mMTris–Malat,pH7.0,0.3Msucrose,
5 mg/ml leupeptin, 0.1 mM PMSF). Rats were anaesthetized
by 3.5 % (v/v) isoflurane inhalation (vaporizer flow rate 0.6–
0.8 l/min) and sacrificed by cervical dislocation. Hearts were
removed immediately andputintoice-coldmediumI.Theleft
ventricles of freshly explanted hearts were cleaned of fat and
connective tissue and cut into small pieces. The pieces were
brieflyrinsedwithice-coldmediumIand homogenisedinice-
cold medium I (5 ml/g tissue) using a Waring blender (for pig
heart) or an Ultra-Turrax device (for rat heart). The homoge-
nate was then centrifuged for 10 min at 5,500×g. The super-
natant was passed through four layers of Miracloth (Merck
Biosciences, Darmstadt, Germany) and centrifuged at
12,000×g for 25 min. The supernatant was again filtered
through four layers of Miracloth and then centrifuged at
143,000×g for 60 min. The resulting pellet was re-
suspended in medium II (20 mM Tris–Malat, pH 7.0, 0.6 M
KCl,0.3 M sucrose,5 mg/ml leupeptin,0.1 mMPMSF) using
an Ultra-Turrax, and the suspension was again centrifuged at
143,000×g for 60 min. The pellet was re-suspended in medi-
um I and again centrifuged at 143,000×g for 60 min. The
pellet from this last centrifugation step was re-suspended in
medium III (20 mM Tris–Malat, pH 7.0, 0.1 M KCl, 0.3 M
sucrose, complete protease inhibitors (Roche, Penzberg, Ger-
many) without EDTA) to give a final protein concentration
between 5 and 10 mg/ml. The suspension was aliquoted,
shock-frozen in liquid nitrogen and stored at −80°C.
Measurement of nucleoside diphosphoribosyl cyclase
activity
Nicotinamide hypoxanthine dinucleotide (NHD) was taken as
a surrogate for NAD to measure ADPR cyclase activity as
described by Graeff et al. (1996). In the reaction catalysed by
the cyclase, NHD is converted to cyclic inosine diphosphor-
ibose (cIDPR) that can be detected via its fluorescence in the
visible spectrum. The following protocol was used to identify
compounds inhibiting the cyclase activity: Test compounds
(stock 3 mM in DMSO) were diluted to 30 μMi nr e a c t i o n
buffer(20mMTris–Malat,pH7.0,0.1MKCl,0.3Msucrose,
complete protease inhibitors without EDTA). In a 384-well
small volume microtitre plate (Greiner Bio-One, Frickenhau-
sen,Germany),2μloftestcompoundswasmixedwith2μlof
cardiac sarcoplasmicreticulum(SR)membranesdilutedinthe
same buffer and incubated for 30 min at room temperature,
and the reaction was started by the addition of 2 μlo f7 5 0μM
NHD in the same buffer. The fluorescence of the reaction mix-
ture (excitation wavelength 275 nm, emission wavelength
410 nm) was measured directly after the addition of substrate
(t0) and after several incubation periods (e.g., 30, 60, 90 min).
Between measurements, the plate was incubated at 37°C. The
cyclaseactivityofeachreactionmixturewasthendefinedbythe
changeinfluorescencewithtime,i.e.,theslopeofthelineinthe
fluorescenceversustimeplotobtainedbylinearregression.
In-gel activity assay
An in-gel activity assay was performed essentially as de-
scribed by Xie et al. (2005), with slight modifications: Rat
cardiac SR preparations were separated on a non-reducing
SDS-PAGE gel (4–12 %). For renaturation of ADPRC, the
gel was incubated for 30 min in 50 mM Tris–HCl, pH 7.4,
and 0.3 % Triton X-100 at room temperature and then
transferred to a buffer composed of 50 mM Tris–HCl,
pH 7.4, and 0.1 % Triton X-100. After 10-min incubation
at ambient temperature, the gel was incubated for 60 min at
room temperature in the same buffer additionally containing
250 μM NHD, and ADPRC was visualised as a fluorescent
band with a UV lamp (254 nm).
Determination of anti-arrhythmic properties of ADPR
cyclase inhibitors in vitro
Anti-arrhythmic properties of cardiac ADPR cyclase inhib-
itors identified with the assay described above were probed
for by determining their ability to prevent the formation of
spontaneous action potentials in guinea pig papillary muscle
cells following high-frequency electrical stimulation. The
experimental protocol was as follows: Guinea pigs (Dunkin
Hardley Pirbright), weighing approximately 400 g, were
sacrificed by concussion followed by exsanguination. Im-
mediately after opening of the thorax, the heart was re-
moved and immersed in Tyrode solution (in millimole per
litre): 136 NaCl, 3.3 KCl, 1.2 KH2PO4, 1.1 MgSO4, 2.5
CaCl2, 5 Glucose, 10 HEPES, pH 7.4, gassed with oxygen),
at room temperature. The left papillary muscle was removed
and mounted in a measuring chamber, containing Tyrode
solution heated to 37°C. The time from removal of the heart
until mounting the papillary muscle in the chamber was
approximately 3 min.
Immediately after mounting of the papillary muscle, it
was stimulated with rectangular pulses of 1 to 4 V and a
duration of 1 to 3 ms, at a frequency of 1 Hz, by means of a
computer programme (MFK, Niedernhausen, Germany).
The bath was continuously perfused with Tyrode solution
using a roller pump (TL, Meredos GmbH, Bovenden, Ger-
many) at a rate of 4 ml/min. The solution was pre-heated to
37°C. Action potentials (APs) were recorded with a glass
Naunyn-Schmiedeberg's Arch Pharmacol (2012) 385:717–727 719microelectrode, filled with 3 M KCl solution. The electrodes
were fabricated from borosilicate glass (item number:
1B150F-4, World Precision Instruments, Sarasota, USA),
by means of a microelectrode puller (DMZ-Universal Puller,
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Fig. 1 a Formation of cIDPR by purified cardiac sarcoplasmic retic-
ulum vesicles. Filled circles, rat cardiac SR; open circles, pig cardiac
SR (n016 each). Specific IDPR cyclase activity was estimated as
6.5 nmol min
−1 mg protein
−1 for rat and 0.63 nmol min
−1 mg protein
−1
for pig SR. b Effect of Zn
2+ ions on the activity of rat cardiac SR
ADPR cyclase, CD38 and A. californica ADPR cyclase. For the rat
cardiac ADPR cyclase, the dashed line denotes the IC50 value that was
determined as 320±55 μM( n03). c In-gel activity assay of partially
purified ADPR cyclase from rat cardiac SR vesicles. Activities in
aqueous solutions of the samples in lanes 2, 3 and 4 corresponded to
21, 15 and 4 RFU/s, respectively
720 Naunyn-Schmiedeberg's Arch Pharmacol (2012) 385:717–727Zeitz Instruments, Martinsried, Germany). The electrodes had
an electrical resistance of 5 to 10 megaohms. The electrical
signal was recorded with an amplifier (Model 309, Harvard
Apparatus GmbH, March-Hugstetten, Germany), and stored
in a computer system.
After an equilibration period of 30 min, an AP was
recorded, and the test substance (or vehicle) was added to
the perfusion solution. Fifteen minutes later, an AP was
recorded, and the perfusion solution was modified: KCl and
KH2PO4 were omitted, and CaCl2 was increased to 5.5 mM.
Afteranadditional15min,anAPwasrecorded,andthetissue
was paced at 4 Hz for 30 s. Then, pacing was stopped, and
frequently, spontaneous APs were observed. The number of
spontaneousAPsoccurringwithin6saftercessationofpacing
was counted. In the presence of vehicle, the number of spon-
taneous APs in the 6-s period was approximately 13. For each
compound tested, ten experiments each for compound and
vehicle control were performed. The number of spontaneous
APs in each group was compared by means of the Student's t
test.
Determination of anti-arrhythmic properties of ADPR
cyclase inhibitors in vivo
Anti-arrhythmic properties of ADPR cyclase inhibitors were
measured in vivo in anaesthetized guinea pigs. For this pur-
pose, guinea pigs were anaesthetized with pentobarbital
(100 mg/kg i.p.) and ventilated with 40 % (v/v)o x y g e n( O 2).
Adequacy of anaesthesia was followed by monitoring of the
vital signs and the palpebral and foot retraction reflexes. After
30 min, the test compound was applied at 3 mg/kg as a bolus
injection. Five minutes later, ouabain was infused at a rate of
30 μg/kg per min, causing a strong continuous increase in
contractility. In the presence of the background sample (bolus
injectionofvehicleonly),ventricularfibrillationwasobserved
approximately 12 min after infusion of ouabain, and cardiac
arrest occurred after approximately 15 min.
Results
Cardiac ADPR cyclase is distinct from CD38
Sarcoplasmic reticulum vesicles prepared from rat or pig
hearts were found to contain ADPR cyclase activity mea-
sured using NHD as a surrogate substrate (Fig. 1a), as
previously described by Meszaros et al. (1997) and Xie et
al. (2005). Unlike CD38, the cardiac SR enzyme was deter-
mined to be inhibited by Zn
2+ (Fig. 1b) showing that the
cardiac protein is different from the known mammalian
ADPR cyclases, CD38 and Bst1/CD157, that are both acti-
vated by Zn
2+ (Hirata et al. 1994; Xie et al. 2005). In an in-
gel activity assay with partially purified rat heart ADPR
cyclase, a single fluorescent band corresponding to an ap-
parent molecular weight of approximately 35 kDa was ob-
served (Fig. 1c), again in line with previous observations
(Xie et al. 2005).
Identification of inhibitors of cardiac ADPR cyclase
A diverse collection of 17,567 small-molecule compounds
was screened at 10-μM concentration for inhibitors of pig
heart ADPR cyclase (Fig. 2). All compounds without auto-
fluorescence observed at t00 that gave >38.2 % inhibition
(mean percent inhibition plus three standard deviations)
were considered as screening hits and re-tested over the
concentration range between 0.3 and 40 μM; 71 compounds
with a concentration response and IC50 values below 40 μM
Fig. 2 High-throughput screen
for small-molecule inhibitors of
cardiac ADPR cyclase. 17,567
compounds were tested at
10 μM for inhibition of pig
cardiac ADPR cyclase. Auto-
fluorescent compounds with
fluorescence at t00 are shown
in light grey and were removed
before further analysis (327
compounds). Horizontal black
lines denote the mean percent
inhibition value over all com-
pounds ± standard deviation
that was determined as −3.2±
13.8. Non-fluorescent com-
pounds with a percent inhibi-
tion above mean + 3 SD were
considered as screening hits (93
compounds)
Naunyn-Schmiedeberg's Arch Pharmacol (2012) 385:717–727 721could be identified. After clustering and testing of com-
pounds with related structures, two structural series could
be identified with activities of their most potent compounds
being in the single-digit nanomolar range. This is several
orders of magnitude more potent than the only previously
described inhibitor of a non-CD38/CD157 mammalian
ADPR cyclase, dihydroxyazobenzene, which was found to
have an IC50 value of >100 μM (Fig. 3), which is in good
agreement with published data (Nam et al. 2006). Further
details and structure–activity relationships for the two series
will be described elsewhere.
Compounds from both series were found to be specific
for the cardiac ADPR cyclase as compared to CD38 and A.
californica ADPR cyclase, again pointing towards the car-
diac protein being structurally and/or mechanistically dis-
tinct from the known ADPR cyclases (Fig. 3). In addition,
two representative compounds, SAN2589 and SAN4825
(for structures, see Fig. 4), were tested for their selectivity
against 33 other proteins. With the exception of the adeno-
sine A2A receptor where ligand binding was inhibited by
81 % in the presence of SAN4825, no binding to any other
tested protein was inhibited by more than 50 % by any of the
two tested compounds tested at 10 μM (Table 1).
Antiarrhythmic activity of cardiac ADPR cyclase inhibitors
Out of the potent and selective inhibitors of cardiac ADPR
cyclase identified in the experiments described above, the two
structurally distinctcompoundsSAN4825andSAN2589were
selected for further characterisation in models of ventricular
arrhythmia. First, both compounds were tested for their ability
to prevent the occurrence of spontaneous action potentials in
guinea pig papillary muscle cells following high-frequency
electrical stimulation. Representative traces are shown in
Fig. 5; the results of the study are summarised in Fig. 6.A t
3 μM, SAN4825 significantly reduced the number of delayed
after depolarisations within 6 s following rapid pacing from
13.1±2.7 to 2.9±1.9 (n010 each, p00.004). With vehicle
only, the number of spontaneous action potentials was equal
to or above 11 in seven out of ten experiments whereas
rat cardiac ADPRC
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Fig. 3 Compounds SAN4825 and SAN2589 are selective inhibitors of
cardiac ADPR cyclase. Inhibition of ADPRC activity of cardiac
ADPRC (upper panel), CD38 (middle panel)a n dA. californica
ADPRC are shown for 4825 (filled circles), 2589 (open circles) and
DHAB (open squares). IC50 values for SAN4825 and SAN2589 on
cardiac ADPRC were determined as 0.13±0.02 and 1.3±0.2 μM,
respectively (n03 each)
N
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Fig. 4 Structures of compound SAN2589 and SAN4825, identified as
potent and selective inhibitors of cardiac ADPR cyclase
722 Naunyn-Schmiedeberg's Arch Pharmacol (2012) 385:717–727addition of SAN4825 reduced the number of spontaneous
electrical activities to equal to or below three in nine out
of ten experiments. There was no difference in membrane
potential (−81.5±5.3 mV for vehicle versus −77.6±
10.2 mV for SAN4825)
This anti-arrhythmic effect was confirmed with the struc-
turally unrelated ADPR cyclase inhibitor, SAN2589 that, at
10-μM concentration, significantly reduced the number of
spontaneous action potentials after high frequency stimula-
tion, from 13.9±2.7 to 4.4±2.3 (n08 and 9, respectively, p0
0.016). Again, no significant differences in membrane poten-
tial were observed (−86.5±5.0 mV for vehicle versus −81.4±
9.2 mV for SAN2589).
Subsequently, compound SAN4825 was tested in an in
vivo model of Ca
2+ overload-induced ventricular arrhythmia
(Fig. 7). Five minutes after an i.v. bolus injection of 4825 or
vehicle at 3 mg/kg, the Na
+/K
+ pump inhibitor ouabain was
infused at a rate of 30 μg/kg per min, leading to a pro-
nounced Ca
2+ overload and the development of ventricular
fibrillation and cardiac arrest within approximately 11 and
14 min, respectively. In this setting, compound SAN4825
was determined to significantly prolong the time between
ouabain infusion and resulting ventricular fibrillation (from
11.1±1.0 to 15.7±1.2 min, n08 each, p00.018) and cardiac
arrest (from 14.2±0.9 to 17.8±0.9 min, n08 each, p0
0.023).
Table 1 Selectivity of
SAN4825 and SAN2589 against
a panel of 33 proteins
Compounds were tested in
duplicates at 10 μM. Results
shown are expressed as percent
activity of control ± standard
deviation
Assay SAN2589 SAN4825
A1 (h) (antagonist radioligand) 83±3 72±1
A2A (h) (agonist radioligand) 61±6 19 ± 1
Alpha 1A (antagonist radioligand) 98±7 94±6
Alpha 2A (h) (antagonist radioligand) 92±12 108±5
Beta 1 (h) (agonist radioligand) 95±1 93±5
Beta 2 (h) (agonist radioligand) 104±8 95±12
CB1 (h) (agonist radioligand) 89±24 89±6
CB2 (h) (agonist radioligand) 101±4 93±1
D1 (h) (antagonist radioligand) 120±1 116±4
D2S (h) (antagonist radioligand) 107±15 89±4
Glycine (strychnine-sensitive) (antagonist radioligand) 109±13 80±6
H1 (h) (antagonist radioligand) 105±10 98±5
H2 (h) (antagonist radioligand) 119±19 90±4
M1 (h) (antagonist radioligand) 102±3 88±3
M2 (h) (antagonist radioligand) 114±2 86±8
M3 (h) (antagonist radioligand) 97±0.4 81±2
N neuronal alpha 4beta 2 (h) (agonist radioligand) 114±10 93±6
N muscle-type (h) (antagonist radioligand) 99±6 96±8
Mu (MOP) (h) (agonist radioligand) 104±6 96±16
PCP (antagonist radioligand) 103±1 117±8
5-HT1A (h) (agonist radioligand) 97±8 107±10
5-HT2A (h) (antagonist radioligand) 123±14 98±5
5-HT2B (h) (antagonist radioligand) 103±5 100 ±9
Ca
2+ channel (L, dihydropyridine site) (antagonist radioligand) 118±29 109±0.2
KV channel (antagonist radioligand) 131±6 93±9
SKCa channel (antagonist radioligand) 88±3 96±0.4
Cl
− channel (GABA-gated) (antagonist radioligand) 97±1 89±0
Norepinephrine transporter (h) (antagonist radioligand) 95±1 102±0.3
dopamine transporter (h) (antagonist radioligand) 103±29 94±5
PDE3A (h) 96±2 90±1
Acetylcholinesterase (h) 107±2 89±5
MAO-A (h) 98±11 98±3
ATPase (Na
+/K
+) 99±1 103±2
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Wehave isolatedsarcoplasmic reticulumvesicles frompig and
rat heart with ADPR cyclase activity as measured using the
surrogate substrate NHD. Inhibition by sub-millimolar con-
centrations of Zn
2+ clearly showed that the enzyme is different
from the two known mammalian ADPR cyclases, CD38 and
CD157, that are both activated by Zn
2+ (Hirata et al. 1994;X i e
et al. 2005). The presence of such an activity has been de-
scribedinearlierreportsfordogandratsarcoplasmicreticulum
(Xie etal. 2005;M e s z a r o se ta l .1997). Material from pig heart
was used to screen for inhibitors of ADPR cyclases, and
compounds with nanomolar affinities to both pig and rat
cardiac ADPR cyclases were identified. In isolated guinea
pig papillary muscle, two compounds from distinct structural
classes were found to significantly inhibit the generation of
pacing-induced spontaneousAPs thatare most likelythe result
of delayed after depolarisations (Hoffman and Rosen 1981;
Hiraoka 1987). In an in vivo model of Ca
2+ overload-induced
ventricular arrhythmia, the ADPR cyclase inhibitor SAN4825
significantly prolonged the time to ventricular fibrillation and
cardiac arrest upon infusion of the glycoside ouabain.
To our knowledge, this is the first description of potent and
selective inhibitors of cardiac ADPR cyclase and their effec-
tiveness as anti-arrhythmic agents. To date, the only known
small-molecule compounds inhibiting a non-CD38/CD157-
like ADPR cyclase are 2,2′-dihydroxyazobenzene (DAB) and
4,4′-dihydroxyazobenzene(DHAB) which was first identified
asaninhibitorofkidneyADPRcyclase(Nametal.2006;Kim
et al. 2008) and later also described as an inhibitor of cardiac
ADPR cyclase (Gul et al. 2009). However, in agreement with
our results, DHAB was determined to be an only moderate
inhibitor of the partially purified ADPR cyclase, with an IC50
value of slightly greater than 100 μM (Nam et al. 2006).
Interestingly, the cellular activity of DHAB as an inhibitor of
angiotensin-II that induced an increase in cADPR and Ca
2+
release in both renal mesangial cells (Nam et al. 2006)a n d
cardiomyocytes (Kim et al. 2008) was much more pro-
nounced—in the nanomolar to low micromolar range—indi-
cating that the cellular activity of the compound may not be
conferred by direct interaction with ADPR cyclase.
Recently, in a set of very elegant studies, Kim and col-
leagues showed that normalization of an angiotensin-II-
dependent increase in cADPR in cardiomyocytes prevents
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Fig. 5 Representative
experimental traces showing the
generation of spontaneous
action potentials in guinea pig
papillary muscle after high-
frequency pacing. At t00, elec-
trical stimulation was switched
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Fig. 6 The ADPR cyclase
inhibitors SAN2589 and
SAN4825 significantly reduced
the number of spontaneous
action potentials observed
within 6 s after high-frequency
pacing of guinea pig papillary
muscle. The given values of n
refer to the number of indepen-
dent experiments (one papillary
muscle isolated per animal)
724 Naunyn-Schmiedeberg's Arch Pharmacol (2012) 385:717–727the sustained rise in [Ca
2+]i and cellular hypertrophy. In
addition, they could demonstrate that the in vitro effect
was translated into an in vivo amelioration of cardiac hy-
pertrophy and an improvement in cardiac function upon i.p.
administration of DAB (1.5 mg/kg/day) in a rat two-kidney-
one-clip (2K1C) model (Kim et al. 2008). In our study
reported here, we show that both in vitro and in vivo, direct
inhibition of ADPR cyclase also has an anti-arrhythmic
effect in models of cellular or cardiac Ca
2+ overload.
Upto50%ofmortalityin heartfailuredoesnotresultfrom
pump failure but from ventricular tachyarrhythmias (Grimm
and Maisch 2002) that are the consequence of dysfunctions in
cardiac Ca
2+ homeostasis: Resting (diastolic) Ca
2+ which is
increased inheart failure(Gwathmeyetal.1990)aswe llasSR
Ca
2+leak in a rare genetic disease called CPVT (Lehnart et al.
2008) can result in transient inward currents mediated by the
sarcolemmal Na
+/Ca
2+ exchanger that, in turn, can lead to
DADs and triggered activity. Both HF and CPVT have been
linkedtoaberrantCa
2+releasethrough‘leaky’RyR2channels
(see Lehnart et al. 2009; Cerrone et al. 2009; Kushnir and
Marks 2010 for recent reviews).
Injection of cADPR at concentrations between 100 nM
and 3 μM into rat ventricular myocytes was reported to lead
to a sustained rise in resting Ca
2+and an increase in the
frequency of spontaneous Ca
2+ waves, while the cADPR
receptor antagonist, 8-amino-cADPR, could reduce number
and amplitude of spontaneous Ca
2+ waves (Prakash et al.
2000). In ventricular myocytes isolated from guinea pig
heart, the cADPR antagonist 8-amino-cADPR suppressed
the formation of isoproterenol-provoked off-trigger action
potentials and Ca
2+ waves and ouabain-induced transient
inward currents whereas cADPR infusion led to generation
of spontaneous action potentials in cardiomyocytes exposed
to ouabain (Rakovic et al. 1999). Other studies in intact
cardiomyocytes have provided additional evidence that
cADPR injection or photorelease increases the magnitude
of Ca
2+ transients, augments contraction and increases the
frequency of occurrence of spontaneous Ca
2+ sparks with
these effects being prevented in the presence of 8-amino-
cADPR or 8-bromo-cADPR (Rakovic et al. 1996; Iino et al.
1997; Cui et al. 1999). In contrast, Guo et al. (1996) ob-
served no effect of cADPR or 8-amino-cADPR on Ca
2+
transients in rat ventricular myocytes (Guo et al. 1996)
Currently, there is only scarce evidence for a potential
regulation of cardiac ADPR cyclase activity or cADPR levels
in disease. On the cellular level, angiotensin-II and isoproter-
enol have been shown to stimulate ADPRC activity and raise
intracellular cADPR (Rakovic and Terrar 2000;H i g a s h i d ae t
al. 2000; Xie et al. 2005; Gul et al. 2008). On the isolated
organ level,an augmentationofcardiac cADPR wasobserved
inLangendorff-perfusedisolatedrabbitheartsuponischemia–
reperfusion(Xieetal.2003).Invivo,asmentionedabove,Gul
et al. (2009) demonstrated a pronounced increase in cardiac
ADPR cyclase activity and cADPR levels in a rat 2K1C
model that is characterised by increased angiotensin-II levels,
hypertension and cardiac hypertrophy. Interestingly, 2K1C
rats display an increased propensity towards ouabain-
induced ventricular arrhythmia (Capasso et al. 1986) which
wasshowntobeimprovedinourstudyherebyadministration
of inhibitors of cardiac ADPR cyclase.
Although cyclic ADP-ribose is well established as an
effective modulator of intracellular Ca
2+ in many cell
types, the mechanism by which cADPR regulates Ca
2+
release remains unclear and is being discussed controver-
sially (see, e.g., Venturi et al. 2010). A direct activation of
RyR2 by cADPR has been proposed on the grounds of
single-channel studies in planar lipid bilayers (Meszaros et
al. 1993; Sitsapesan et al. 1994). However, activation of
Ca
2+ release by cADPR was reduced in the presence of
ATP suggesting that under physiological conditions, at
Fig. 7 Compound SAN4825,
at 3 mg/kg i.v., significantly
prolongs the time to ventrular
fibrillation (VF) and cardiac
arrest (CA) upon infusion of
ouabain at 30 μg/kg/min
Naunyn-Schmiedeberg's Arch Pharmacol (2012) 385:717–727 725millimolar ATP concentrations, cADPR has no activating
effect (Sitsapesan et al. 1994). In addition, other groups
have reported that cADPR does not alter the open proba-
bility of RyR2 in planar lipid bilayers (Fruen et al. 1994;
Copello et al. 2001) or that activation by cADPR is lost in
the absence of FK-506 binding protein 12.6 (FKBP12.6,
Tang et al. 2002) The latter effect was recently also de-
scribed in intact mouse cardiomyocytes, where the increase
in Ca
2+ spark frequency upon cADPR injection was not
observed in cardiomyocytes derived from FKBP12.6-
knockout animals (Zhang et al. 2009). In the same study,
it was also demonstrated that cADPR could displace
FKBP12.6 from cardiac SR vesicles. Thus, another theory
regarding the mode of action of cADPR is that of an
indirect interaction with RyR2 via binding to FKBP12.6.
However, other reports indicate that FKBP12.6 itself may
have no influence on RyR2 opening (Barg et al. 1997;
Stewart et al. 2008;X i a oe ta l .2007). In addition, a role
of cADPR in the regulation of the activity of sarcoplasmic
reticulum Ca
2+ ATPase has been discussed (Lukyanenko et
al. 2001): In the presence of cADPR, there was an increase
in the rate of Ca
2+ uptake into cardiac SR vesicles, an
elevated SR Ca
2+ content in permeabilized ventricular
myocytes and, as a consequence of this rise in luminal
Ca
2+, an increase in the frequency of Ca
2+ sparks that
was inhibited by 8-Br-cADPR. This illustrates that the
mechanism of action of cADPR on SR Ca
2+ release is
complex and is still incompletely understood. It is a limi-
tation of our study that we could not investigate the effects
of our compounds on key Ca
2+-handling proteins apart
from ADPR cyclase—the molecular correlate of which is
unknown—and the proteins summarised in Table 1.N e v -
ertheless, their potency in inhibiting ADPR cyclase activity
and selectivity versus a broad panel of diverse targets
suggest that the two compounds could be valuable tools
to further elucidate the mechanism of cADPR-induced
Ca
2+ r e l e a s eb o t hi nv i t r oa n di nv i v o .
In summary, we have identified potent and selective
inhibitors of mammalian cardiac ADPR cyclase that are
distinct from the known mammalian ADPR cyclases CD38
and Bst1. Cardiac ADPR cyclase inhibitors from two dif-
ferent structural classes were able to suppress pacing-
induced delayed after depolarisations in guinea pig cardio-
myocytes. In vivo, compound SAN4825 significantly
delayed ventricular fibrillation and cardiac arrest after oua-
bain infusion in guinea pigs. Cardiac ADPR cyclase inhib-
itors may thus provide a novel therapeutic principle for the
prevention of ventricular arrhythmias, e.g., in conditions of
catecholaminergic ventricular tachycardia or congestive
heart failure.
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